Skip to main content

Advertisement

Table 2 Overview of the single-nucleotide sequence variants considered in the present work

From: Influence of oxytocin receptor single nucleotide sequence variants on contractility of human myometrium: an in vitro functional study

VariantVariant-typePosition (Ch37) aMAF
(Eur.) b
MAF
(study) c
Genotype (REF/MA)Association
rs10427783’UTRg.87945450.380.41(G/T)maximal oxytocin infusion rate / total oxytocin dose [11]
rs11706648Introng.87965470.320.28(A/C)maximal oxytocin infusion rate [11]
rs237888Introng.87970950.060.05(T/C)cesarean section [11]
rs4686301Introng.87985860.310.26(C/T)maximal oxytocin infusion rate / total oxytocin dose [11]
rs53576Intron3g.88043710.350.34(G/A)time from latent to active labor [10]
rs237895Introng.88074230.410.42(C/T)maximal oxytocin infusion rate [11]
rs237902Exon 3g.88091840.330.32(G/A)preterm birth (suggestive) [8]
rs4686302Exon 3g.88092220.120.13(C/T)preterm birth [8]
  1. MAF Minor allele frequency
  2. REF/MA Reference /Minor Allele gene
  3. a position according to the genomic reference sequence NCBI Build 37.3 GRCh37.p5 assembly
  4. b in the European population (all available EUR subgroups) according to the 1000 Genomes EUR population (SNPnexus http://snp-nexus.org)
  5. c in the present study population